Early administration of 4-factor prothrombin complex concentrate (4F-PCC) was of no benefit to patients with trauma at risk of massive transfusion, the randomized PROCOAG trial from France showed.

Among over 300 patients with the highest trauma level activation, the absolute difference in median total 24-hour blood product consumption between the 4F-PCC and placebo groups was 0.2 U, reported Pierre Bouzat, MD, PhD, of Hôpital Albert Michallon in Grenoble, France, and co-authors.

Furthermore, 35% of patients in the 4F-PCC group presented with at least one thromboembolic event compared with 24% of the placebo group.

Read More